Aslani, Nikka M.
HRN: 21-81-63 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/30/2025
CEFUROXIME 750MG (VIAL)
05/30/2025
06/06/2025
IV
360mg
Q8H
PCAP C
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes